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Highlight 
 We identified 60 good quality RCTs using CAM as intervention for patients with rheumatic 
diseases. Treatment modalities include acupuncture, Ayurvedic treatment, homeopathic 
treatment, electricity, natural products, megavitamin therapies, chiropractic or osteopathic 
manipulation, and energy healing therapy. 
 Evidence indicates that some CAM therapies may be useful for rheumatic diseases, such as 
acupuncture for osteoarthritis. 
 There were only minor adverse reactions observed for CAM interventions presented. 
 
 
 
ABSTRACT 
Objectives: 
To summarize all good quality randomized controlled trials (RCTs) using complementary and alternative 
medicine (CAM) interventions in patients with rheumatic diseases.   
Methods: 
A systematic literature review guided by the Preferred Reporting Items for Systematic review and Meta-
Analysis (PRISMA) was performed. We excluded non–English language articles and abstract-only 
publications. Due to the large number of RCTs identified, we only include “good quality” RCTs with Jadad 
score of five.  
Results: 
We identified 60 good quality RCTs using CAM as intervention for patients with rheumatic diseases: 
acupuncture (9), Ayurvedic treatment (3), homeopathic treatment (3), electricity (2), natural products 
(31), megavitamin therapies (8), chiropractic or osteopathic manipulation (3), and energy healing therapy 
(1). The studies do not seem to suggest a particular type of CAM is effective for all types for rheumatic 
diseases. However, some CAM interventions appear to be more effective for certain types of rheumatic 
diseases. Acupuncture appears to be beneficial for osteoarthritis but not rheumatoid arthritis. For the 
other therapeutic modalities, the evidence base either contains too few trials or contains trials with 
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contradictory findings which preclude any definitive summary. There were only minor adverse reactions 
observed for CAM interventions presented. 
Conclusion: 
We identified 60 good quality RCTs which were heterogenous in terms of interventions, disease, measures 
used to assess outcomes, and efficacy of CAM interventions. Evidence indicates that some CAM therapies 
may be useful for rheumatic diseases, such as acupuncture for osteoarthritis. Further research with larger 
sample size is required for more conclusive evidence regarding efficacy of CAM interventions.  
 
Keywords: Rheumatic diseases, complementary and alternative medicine, systematic review 
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Introduction 
Rheumatic diseases encompass a broad spectrum of musculoskeletal, arthritic and connective tissue 
disorders, including rheumatoid arthritis (RA), osteoarthritis (OA), fibromyalgia, gout, vasculitides, 
systemic sclerosis, systemic lupus erythematosus (SLE), ankylosing spondylitis and psoriatic arthritis 1. 
Rheumatic diseases are associated with reduced productivity, significant disability and lowered quality of 
life 2. Conventional therapies for rheumatic diseases include nonsteroidal anti- inflammatory drugs 
(NSAIDs), disease- modifying anti- rheumatic drugs (DMARDs) and biologics 3. However, some patients do 
not respond well to these conventional therapies 4. Thus, patients with rheumatic diseases often seek 
other forms of treatments such as complementary and alternative medicine (CAM) 5.  
The World Health Organization has defined CAM as ‘A broad set of healthcare practices that are not part 
of the country’s own tradition and are not integrated into the dominant healthcare system’ 6. CAM covers 
a spectrum of approaches that may prevent or treat diseases. CAM practices may be systematically 
divided into five main categories: alternative medical systems (for example homeopathy and 
acupuncture), biologically based therapies (for example herbal products, dietary constituents or additives 
that are fund in nature), manipulative and body- based therapies (for example massage, chiropractic and 
osteopathic manipulation), mind- body therapies (for example meditation, hypnosis, cognitive therapy, 
patient support groups and prayer) and energy healing therapies (for example Qi gong, reiki and 
therapeutic touch methods) 7. Previous studies indicated that 60% to 90% of patients with rheumatic 
diseases have used some form of CAM 5, 8. Rheumatological conditions are also among the commonest 
disease conditions encountered by CAM practitioners 9.  
The underlying mechanisms for the efficacy of CAM have not been elucidated fully. It has been 
hypothesized that acupuncture may block the pain pathways by releasing encephalin 10; Tripterygium 
wilfordii  (also known as Thunder God Vine) 10, rose-hip 11, andrographolide (extracted from Andrographis 
paniculata) 12, Nigella sativa oil capsules 13, GCSB-5 (a traditional medicine preparation) 14, Ganoderma 
lucidum (more commonly known as Ling Zhi) when combined with San Miao San (a herbal remedy used 
empirically to treat arthritis) 15, Avocado–soybean unsaponifiable—Expanscience (ASU-E) 16, chondroitin 
17, glucosamine sulfate 17, alpha-linolenic acid 18, gammalinolenic acid (found in borage seed oil) 19, willow 
bark 20, antioxidant vitamins such as Vitamin C and Vitamin E 10, and electroacupuncture 10, may help to 
lower the level of pro-inflammatory cytokine; Carnitine 21 and Aflapin® 22 may have anti-inflammatory 
properties by exerting its effects on lipid peroxidation and matrix metalloproteinase respectively. 
Dehydroepiandrosterone (DHEA) and Vitamin D may help to alleviate symptoms of rheumatic diseases 
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through its immunoregulatory properties 23, 24. Plant- derived polysaccharides may be important to 
modulate the gastrointestinal microbial 25, when may be important in pathogenesis of rheumatic diseases 
26. Vitamin K may be important for bone metabolism 27. The mechanism of homeopathy and Ayurvedic 
medicine is less clear, but there is some evidence suggesting that their antioxidant properties may be 
responsible to alleviate the symptoms of rheumatic diseases 28, 29. Similarly, the mechanism of electrical 
stimulation is still speculative, though it is generally believed that the effects are primarily mediated 
through direct actions on the brain 30. It has been proposed that manual therapy can act on the central 
pain pathways 31. There is no clearly mechanism of action for magnets, although it might involve reduction 
of inflammation 32. The growing interest in CAM among patients with rheumatic diseases clearly indicates 
the need for a more thorough investigation of both the efficacy and safety of CAM. 
Currently, there is a large number of studies evaluating different forms of CAM for rheumatic patients 
with rheumatic diseases 33, 34. However, there has been no systematic review with clear quality assessment 
encompassing various categories of CAM used in patients with rheumatic diseases. Therefore, we aimed 
to conduct a systematic review including all randomized controlled trials (RCTs) using some form of CAM 
intervention in patients with rheumatic diseases.   
Methods  
Search strategy 
We identified potentially relevant articles using PubMed® and Embase® searches. Literature review start 
date was unrestricted and was current as of May 2017. A search strategy (Supplemental Table 2) of three 
components was used: (1) disease terms (2) keywords of the CAM and (3) randomized controlled trials. 
The disease terms were adapted from a previously published paper regarding rheumatic diseases 35. 
Keywords of CAM interventions include the treatments listed in the 2002 and 2007 NCCAM report 
regarding prevalence of CAM in United States 7, 36. We also reviewed reference lists and searched previous 
reviews on similar topics. 
Inclusion criteria  
Two authors (JKP and HG) independently screened the titles of selected articles and excluded duplicates 
and those obviously irrelevant. Two authors reviewed abstracts and full-text articles against prespecified 
eligibility criteria. We included RCTs of CAM conducted among patients with rheumatic diseases. We 
excluded non–English language articles and abstract-only publications. The references of all selected 
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relevant articles were manually searched to obtain additional relevant publications. Any disagreement 
was resolved by discussion to reach consensus.  
Data extraction and Quality Assessment  
One investigator (JKP) extracted study data, and a second (HG) verified the accuracy of the extractions. 
The data items extracted were: sample size, age, disease, experimental design, characteristics of the 
intervention in all trial arms including type and dose of therapy, primary and secondary outcome 
measures, findings and side effects. Two investigators independently assessed the quality of each study 
using the Jadad scoring system 37. The Jadad scale is a scoring system that has three items adding up to a 
maximum score of 5. Zero, one, or two points can be given for randomization and double-blinding; zero 
or one point for the description of drop-outs and withdrawals. It should be noted that for Jadad scoring 
system, double blinding was considered appropriate if it was stated or implied that neither the evaluator 
nor the subject could identify the intervention being assessed 37. The Jadad scoring system is relatively 
straightforward to apply and was chosen because it has been shown to present the best validity and 
reliability evidence for assessment of methodological quality of RCTs 38. Given the large number of RCTs 
of CAM among patients with rheumatic diseases, only RCTs with a Jadad score of five were included in the 
review. Risk of bias was assessed using Jadad scoring.   
Data presentation 
We presented primary outcome measures, findings, comments and adverse events for each trial, 
categorized by the type of therapy, to allow readers to understand the benefit and risk associated with 
each therapy. We also present the control used in each study. For this review, placebos are defined as 
inactive substances used to compare results with active substances while sham treatments refer to false 
treatments for procedures. Secondary outcomes and measures can be found in supplementary data.  
Results 
As shown in Figure 1, we identified 5,472 records from our searches in Embase® and Pubmed®. After 
removing 798 duplicates, 4674 articles remained. Of these, 501 articles were deemed relevant after title 
and abstract screening. Of the 501 articles, 441 articles did not meet the inclusion criteria as JADAD score 
was less than 5. A total of 60 articles met the inclusion criteria. We did not identify any additional articles 
from hand-searching.  
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Our literature search has identified 60 good quality RCTs using CAM as intervention for patients with 
rheumatic diseases: 9 RCTs for acupuncture, 3 concerning Ayurvedic treatment, 3 RCTs for homeopathic 
treatment, 2 RCTs using electricity, 31 RCTs examining nonvitamin, nonmineral, natural products, 8 
assessing megavitamin therapies, 3 RCTs looking at chiropractic or osteopathic manipulation, and 1 RCT 
examining energy healing therapy (Table 1).  
Acupuncture 
We have identified nine high quality RCTs concerning acupuncture for patients with rheumatic diseases. 
Six RCTs reported no statistically significant difference between experimental and control groups 39-44, 
while the remaining three RCTs showed that acupuncture had beneficial effects for patients with 
rheumatic diseases, especially knee OA 45-47. For RA, the evidence seems to be clearly negative with all 
three available RCTs demonstrating no beneficial effects 40-42. A wide range of acupuncture treatment 
protocol was used, with different frequency of treatment, length of treatment, number of acupuncture 
points and usage of electric current. In addition, the sham or placebo treatments used in the studies were 
heterogenous, with some using real acupuncture points but with no skin penetration 39, 40, superficial 
acupuncture at non- acupuncture points 41, or needle quickly withdrawn after skin puncture 42. There were 
also different modalities of acupuncture treatment, including traditional acupuncture without electricity 
40, 41, 44, 46, laser acupuncture 45, dry needling 39, gold bead implantation 43, electroacupuncture 42, and 
moxibustion 47. Gold bead implantation at acupuncture points did not result in any significant differences 
in pain, stiffness and function among patients with knee OA 43. Moxibustion, is a non-invasive procedure 
that involves burning moxa, the herb Artemisia vulgaris, at acupuncture points 48. Among patients with 
knee OA, moxibustion treatment appeared to improve function and pain score 47. Similarly, laser 
acupuncture appeared to be beneficial for patients with knee OA 45. Dry needling, which involves placing 
needles at trigger points, was found to lower pain among patients with myofascial pain syndrome 39. 
Ayurveda 
The three RCTs investigating Ayurvedic medicine (classical Hindu medical tradition) in patients with RA 
(N=1) and knee OA (N=2) did not show statistically significant between- group differences in the outcomes 
evaluated 49-51.  
Homeopathic treatment 
We have identified three high quality RCTs on homeopathic treatment, which is a treatment developed 
by Samuel Hahnemann 52. Homeopathy uses preparations of substances whose effects when 
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administered to healthy subjects correspond to the manifestations of the disorder in the individual patient 
52. Only one high quality RCT investigating homeopathy showed significantly greater improvements in 
primary outcomes evaluated including tender point count (p<0.05) and tender point pain (p<0.01), quality 
of life (p<0.05) and global health (p < 0.05) for patients with fibromyalgia (FM) 53, while the other RCTs 
concluded that homeopathic treatment appeared to have no beneficial effects for RA and knee OA 54, 55. 
There were two good quality RCTs investigating the use of electricity on FM and RA. However, conflicting 
results exist as electrical stimulation appeared to be beneficial for FM but not RA 56, 57.  
Nonvitamin, nonmineral, natural products  
Among the thirty one RCTs concerning nonvitamin, nonmineral, natural products, most of them 
investigated patients with RA (N=11, 34%) and OA (N=15, 47%). There were only five high quality RCT 
investigating the effect of natural products on rheumatic diseases other than RA and OA: one article each 
on DHEA for FM 58, one investigated Traditional Chinese medicine (TCM) for Sjögren's syndrome 59, one 
investigated Chuanhu anti-gout mixture 60, one investigated TCM for SLE 61 and one on TCM for IBS-C 62. 
Twenty one out of the twenty nine RCTs concerning nonvitamin, nonmineral, natural products included 
placebo control. Fourteen placebo-controlled studies on nonvitamin, nonmineral, natural products 
showed beneficial effects of CAM on rheumatic diseases: ShengJinRunZaoYangXue for Sjögren's syndrome 
59, Chinese Herbal medicine for IBS-C 62, Tong Luo Hua Shi capsules for RA 63, Rose-hip for RA 64, Mahame-
Mafasel pomade for knee OA 65, Aflapin for knee OA 66, 4Jointz cream for knee OA 67, topical Tripterygium 
wilfordii for RA 68, oral GCSB-5 for hand OA 69, rose-hip for knee and hip OA 70, willow bark extract for knee 
and hip OA 71, methylsulfonylmethane (MSM) for knee OA 72, L-carnitine for knee OA 73 and topical 
glucosamine and chondroitin preparation for knee OA 74. Placebo- controlled studies investigating 
Ambrotose Complex containing dietary plant- derived polysaccharides for RA 75, Ganoderma lucidum (Ling 
Zhi) and San Miao San for RA 76, Andrographolides, which is extracted from Andrographis paniculata, for 
RA 77, Nigella sativa oil capsules for RA 78, Alpha-linolenic acid for RA 79, Huo-Luo-Xiao-Ling capsules for 
knee OA 80, and ASU-E for hip OA 16, failed to show beneficial effects. A study demonstrated that change 
in steroid dose was not significantly different between patients with SLE who received 100% Dan-Chi-Liu-
Wei combination, a traditional Chinese medicine (TCM), and those who received only 10% TCM 61.  
Though topical glucosamine and chondroitin preparation may have beneficial effects for knee OA 74, 
interestingly, there were another that looked at the orally administered glucosamine, but did not find 
evidence supporting the efficacy of glucosamine. Overall, the two studies constituted conflicting evidence 
for that glucosamine is effective for knee OA 74, 81. Another study comparing reparagen, a dietary 
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supplement derived from South American botanicals, and glucosamine found that both produced 
substantial improvements in pain 82.  
Five studies on nonvitamin, nonmineral, natural products were non-inferiority studies- one study showed 
that SKI306X, which consists of biologically active ingredients from three plants, was not inferior to 
celecoxib for patients with RA 83, another study showed that Chuanhu anti-gout mixture, a TCM, was not 
inferior to colchicine 60; a study demonstrated that GCSB-5 is comparable to Celecoxib in terms of the 
efficacy and safety for treatment of OA of knee joint 84; another study demonstrated that treatment with 
MD-Knee was not inferior of the treatment with SUPARTZ® (sodium hyaluronate), with a confidence level 
higher than 99% 85; another study could not confirm the premise of combination of borage and fish oils 
would be superior to either oil alone 86. 
In a study looking at orally administered T. wilfordii based therapy 87, RA patients were classified into 
predictor positive (P1) and predictor negative (P2) group, and were randomly assigned to accept the T. 
wilfordii based therapy and Methotrexate and Sulfasalazine combination therapy (M&S) for 24 weeks, 
respectively. The ACR 20 responses were 82.61% in TwHF/P1 group, significantly higher than that in 
TwHF/P2 group and in M&S/P1 group but not higher than in M&S/P2 group.  
Megavitamin therapy 
There were two high quality RCTs investigating the effect of Vitamin D supplementation on knee OA 88, 89. 
However, conflicting evidence exists concerning the supplementation of vitamin D in knee OA condition. 
Lastly, Vitamin E, and magnesium-, calcium-rich supplement appeared to have no beneficial effects for 
patients with knee OA 90, 91. One study has found that Vitamin D supplementation improved the disease 
activity of juvenile SLE, though it should be noted that the sample size of the study might be small with 
only forty patients in total 92. It was also found that Vitamin K supplementation at 10 mg/day for 8 weeks 
did not alter joint destruction and immune status in the patients with RA compared with the controls 93. 
A pilot, small- sample study among thirty four adults with fibromyalgia syndrome failed to show efficacy 
of Myers’ Cocktail, a solution containing Vitamin B and C 94. However, calcium supplementation improved 
the total body bone mineral density among young adults with RA 95.  
Chiropractic or osteopathic manipulation 
We identified three studies examining chiropractic or osteopathic manipulation. Two of the studies were 
from the same group and both reported beneficial effects of manual treatment including mobilization for 
specific subtypes of rheumatic diseases - Carpometacarpal joint OA and Thumb carpometacarpal OA 96, 97. 
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Kinesio taping, which involves placing elastic adhesive material, appeared to have no beneficial effects for 
RA 98.  
Energy healing therapies 
There was only one high quality RCT investigating magnetic bracelet and no beneficial effects was 
reported 99.  
Discussion 
The studies presented in this systemic review were heterogenous in terms of interventions, disease, 
measures used to assess outcomes, and efficacy of CAM interventions. The studies do not seem to suggest 
a particular type of CAM is effective for all types for rheumatic diseases. However, some CAM 
interventions appear to be more effective for certain types of rheumatic diseases, such as acupuncture 
for OA. Most of the high quality RCTs focused on osteoarthritis (N=30, 50%), possibly because currently 
OA has no effective therapy 100. Therefore, the treatment of OA is primarily focused on managing the 
condition by minimizing morbidity and maximizing quality of life 101, and there is growing interest for 
patients with knee OA to seek CAM such as acupuncture, glucosamine and vitamin D supplementation to 
alleviate arthritic symptoms 102, 103. Relatively clear consensus exists that acupuncture is effective for OA, 
especially knee OA, which can be seen in this systematic review as well as previous systematic review 104. 
However, only a moderate effect of glucosamine has been demonstrated for knee OA, which is in 
agreement with the conclusion of previous systematic review 105. Our systematic review also found that 
there is conflicting evidence regarding the use of vitamin D supplementation for knee OA, which also is in 
agreement with previous systematic review 106. For the other therapeutic modalities, the evidence base 
either contains too few trials or contains trials with contradictory findings which preclude any definitive 
summary. 
We identified eighteen good quality RCTs assessing CAM interventions among patients with RA. For RA, 
the good quality RCTs failed to show specific effects of acupuncture for patients, which is in agreement 
with previous systematic review 107. Among the nonvitamin, nonmineral, natural products investigated, 
only Tripterygium wilfordii and Tong Luo Hua Shi have beneficial effects on the symptoms of RA 63, 68, 87.   
For fibromyalgia, there was some evidence regarding the efficacy of homeopathic treatment and cranial 
electrical stimulation in decreasing pain. For Sjögren's syndrome, there was one trial demonstrating the 
efficacy of ShengJinRunZaoYangXue granules. Another trial showed that Chinese Herbal Medicine capsule 
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can significantly improve the global symptom improvement of patients with constipation-predominant 
irritable bowel syndrome. 
The CAM interventions in this review had minor or no side effects reported. Notable adverse reactions 
were observed in patients treated with a particular Ayurvedic formulation which might be associated with 
elevated serum glutamic pyruvic transaminase (SGPT) level 51, Tripterygium wilfordii  (also known as 
Thunder God Vine) supplementation tends to be associated with diarrhea, frequent withdrawal form 
therapy, nausea, dyspepsia, abdominal pain, male infertility, dysmenorrhea 87, androgenic side effects 
associated with DHEA supplementation 58, and possible hypercalcemia from vitamin D supplementation 
88.  
There were some limitations to this review. Due to the large number of interventions, reviewing all 
primary literature was not feasible. We only included higher-quality RCT with Jadad score of 5 that were 
most relevant to the review scope. The Jadad scoring system was chosen because it has been shown to 
present the best validity and reliability evidence for assessment of methodological quality of RCTs 38. 
Studies are scored according to the presence of three key methodological features of clinical trials, 
specifically randomization, double-blinding, and accountability of all patients 108. It has been suggested 
that heightened placebo effects are especially prominent in trials concerning CAM, highlighting the need 
for randomization and double-blinding 109. However, some CAM treatment approaches such as spa and 
yoga do not have obvious suitable double- blinded control. For such CAM interventions, Jadad scoring 
system may not be suitable. However, as the aim of this systematic review is to summarize the available 
good quality RCTs involving CAM interventions for patients with rheumatic diseases, it was necessary to 
conduct quality assessments of the RCTs. Among the common trial quality assessment tools, only Jadad 
scoring system does not require the care provider or those administering the intervention to be blinded 
to treatment allocation 108. This allows evaluator- and subject- blinded RCTs, which are common in invasive 
interventions such as acupuncture 39-41, to be included in the analysis. Moreover, conventional therapies 
such as analgesia and physiotherapy may confound the results of the trials. However, as the reporting of 
the use of conventional therapies is not clear in the studies included, we could not assess the impact of 
the conventional therapies on the results of the trials. Future research should provide more insight in this 
area. In addition, we excluded non–English-language articles which may contain relevant studies on CAM 
widely practised in non- Western culture. Moreover, the existence of publication bias in research may 
lead to an overestimate of treatment efficacy of CAM interventions 110. Limitations also existed in the 
evidence base. For each CAM intervention, trials were heterogeneous in terms of study design. Different 
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dosage, number of treatment sessions, duration, frequency of sessions, methods of assessing outcomes 
and efficacy, and statistical analysis were employed for each study, making it difficult to compare results 
across studies. Therefore, standardization in CAM treatment modality in trials may be useful to elucidate 
the efficacy of the various CAM treatment modalities. 
In conclusion, we identified 60 good quality RCTs which were heterogenous in terms of interventions, 
disease, measures used to assess outcomes, and efficacy of CAM interventions. Several CAM interventions 
are associated with beneficial effects for patients with rheumatic diseases. Relatively clear consensus 
exists that acupuncture is effective for OA, especially knee OA. Only Tripterygium wilfordii and Tong Luo 
Hua Shi have beneficial effects on the symptoms of RA, while all the other CAM interventions are equivocal 
or of no benefit. Further research in CAM interventions should focus on good quality trials with larger 
sample size before progressing to pragmatic trials to evaluate the effectiveness of the CAM interventions. 
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 Figure 1. Flow chart on selection of articles for review 
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Table 1: Characteristics of good quality trials of complementary and alternative medicine as defined by 
NCCAM in patients with rheumatic diseases 
Re
f  
N; 
mea
n 
age 
(yea
rs)  
Dise
ase  
Intervention (name; dosage or 
frequency; duration) 
Primary 
Outcomes 
Measures 
 
Findings and 
Comments 
Side effects  
Desi
gn 
Experiment
al  
Control  
Acupuncture  
[3
9] 
39; 
42 
MPS 1:1 Dry 
needling; six 
sessions; 4 
weeks 
 
Blunted 
needle 
without 
penetratio
n of skin  
Pain measured 
using VAS 
Pain was significantly 
lower in the dry 
needling group 
(p<0.001). 
Not 
reported  
[4
0] 
56;  
Me
an 
age 
not 
rep
orte
d  
RA 1:1 
Cros
s-
over 
Acupunctur
e; 5 
treatments 
at weekly 
interval  
Needle 
introducer 
held 
without 
pressure 
and no 
skin 
penetratio
n 
ESR, CRP, VAS 
p, VAS G, 28 
swollen joint 
count, 28 
tender joint 
count, GHQ 
and modified 
DAS index 
No significant 
difference between 
two sequence groups 
except for GHQ 
anxiety.  
 
No AEs 
reported 
[4
1] 
40; 
50  
RA 1:1 Acupunctur
e; Two 
sessions 
weekly; 5 
weeks 
Superficial 
acupunctu
re at non- 
acupunctu
re points  
Proportion of 
patients who 
reached ACR20 
response 
 
At week 5, there was 
no significant 
difference between 
intervention groups.  
 
AEs minimal 
[4
2] 
36; 
58  
RA 1:1:
1 
1. EA; 2. 
TCA; 
Two 40 min 
sessions 
weekly; 10 
weeks 
 
Needle 
was 
quickly 
withdrawn 
after 
puncturing 
skin to a 
depth of 
2mm 
Changes in the 
pain score at 
week 10  
  
At week 10, the pain 
score remained 
unchanged in all 3 
groups. 
 
AEs minimal  
[4
4] 
213; 
60  
Knee 
OA 
1:1  Acupunctur
e; 12 
sessions; 6 
to 12 weeks  
Identical-
appearing 
nonpenetr
ating 
Streitberg
er 
needles 
Change in 
WOMAC total 
score from 
baseline to 12 
weeks  
 
No significant 
difference between 
groups in primary 
outcomes evaluated. 
 
17 AEs in 
experiment
al group and 
15 AEs in 
control 
group  
[4
5] 
55; 
53  
Knee 
OA 
1:1 Laser 
acupunctur
e; 20 min 
per day and 
5 days per 
week; 10 
days 
Sham 
laser 
therapy, 0 
J/cm2  
pVAS, 50-foot 
walking time, 
knee 
circumference, 
MTS, and 
WOMAC 
 
Statistically 
significant 
improvement was 
observed in PVAS, 50 
foot w, and KC in 
experimental group. 
In control group, 
Not 
reported  
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statistically significant 
improvement was 
observed in PVAS, 50 
foot w, and WOMAC.  
[4
6] 
570; 
65.5  
Knee 
OA 
1:1:
1 
Electroacup
uncture; 23 
sessions 
over 26 
weeks 
1. Same 
active 
needle 
placement 
but no skin 
puncture 
2. 
Education
al control  
WOMAC 
function and 
pain score  
 
Greater improvement 
in WOMAC function 
scores in experimental 
group (p=0.01), 
WOMAC function 
score (p= 0.01), 
WOMAC pain score 
(p= 0.003). 
7%, 3% and 
4% of 
participants 
in 
acupunctur
e, sham and 
educational 
control 
group 
experienced 
AEs 
[4
3] 
40; 
68  
Knee 
OA 
1:1  Gold bead 
implantatio
n through 
needles at 
acupunctur
e points  
No gold 
bead 
implantati
on after 
placing 
needles at 
acupunctu
re points  
Patient’s 
assessment of 
knee pain, 
knee stiffness 
and knee 
function as 
well as 
physician’s 
rating of knee 
and knee 
function  
No significant 
difference between 
experimental and 
control group in all 
outcomes evaluated 
(all p-values> 0.05). 
Differences in the use 
of analgesics at the 
beginning and at the 
end of the study 
cannot be detected 
with certainty due to 
small sample size.  
Not 
reported 
[4
7] 
110; 
65 
Knee 
OA 
1:1  Moxibustio
n; three 
times a 
week; 6 
weeks 
Sham 
device 
with 
insulated 
metal 
membran
e which 
isolates 
the smoke 
and heat 
WOMAC pain 
and function 
scores taken at 
the end of the 
6-week course 
of treatment 
WOMAC pain scores 
showed greater 
improvement in the 
active treatment 
group than in control 
at Week 6 (p<0.001) as 
did WOMAC physical 
function scores of the 
active treatment 
group at week 6 (p= 
0.015). 
No 
significant 
AEs were 
found 
Ayurveda 
[4
9] 
182; 
45  
RA  1:1 RA-I; 
444 mg/day; 
16 weeks  
Placebo  Reduction of 2 
grades or from 
grade 2 to 
grade 1 in 
patient and 
physician GA; 
and ACR20 
 
No significant 
difference between 
groups in primary 
outcomes evaluated. 
 
No 
significant 
differences 
in the side 
effects 
profile 
between 
groups 
[5
0] 
236; 
54  
Knee 
OA 
1:1:
1:1:
1:1:
1 
1. Shunthi + 
Guduchi + 
Gokshur  
1. Placebo 
(Maize 
starch) 
Active pain and 
WOMAC index 
No significant 
difference (p < .05) for 
pain (weight bearing) 
and WOMAC 
Only Mild 
AEs were 
reported 
. 
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2. Shunthi + 
Guduchi + 
Ashwagand
ha + 
Gokshur  
3. Shunthi + 
Guduchi + 
Amalaki  
4. Shunthi + 
Guduchi  
5. Shunthi + 
Guduchi + 
Ashwagand
ha  
2. 
Glucosami
ne 
sulphate 
questionnaire (knee 
function); placebo 
response was high. 
[5
1] 
418; 
55.5  
Knee 
OA 
1: 
1:1:
1 
1. SGCG 
Ayurveda 
formulation 
2. SGC 
Ayurveda 
formulation 
 
1. 
Glucosami
ne 
2. 
Celecoxib 
Active pain, 
WOMAC pain 
and functional 
score  
 
Significant 
improvement was 
seen in each of the 
intervention groups. 
Difference between 
any two intervention 
groups for the mean 
change from baseline 
to completion for 
primary efficacy 
measure was within 
the equivalence 
range. 
ADR: 29% 
Seven 
patients in 
experiment
al group 
were 
withdrawn 
and SGPT 
normalized 
after 
stopping the 
drug. 
Homeopathic treatment  
[5
3] 
62; 
49  
FM 1:1 LM; 
1/50000 
dilution; 4 
months 
Placebo McGill Pain 
Questionnaire, 
Appraisal of 
Fibromyalgia 
QoL scale, 
global self-
rated health 
scale, and 
POMS scale 
Participants on active 
treatment showed 
significantly greater 
improvements in 
tender point count (p< 
0.05) and tender point 
pain (p< 0.01), quality 
of life (p< 0.05) and 
global health (p< 
0.05). 
No patient 
withdraw 
due to ADR  
[5
4] 
56; 
64  
RA 1:1 1. 
Individualize
d 
homeopath
y prescribed 
as tablets 
2. 
Standardize
d 
commercial 
homeopathi
c complex 
Placebo  ACR20 
response and 
improvement 
in the patient’s 
GA of health 
using 100-mm 
VAS 
No significant 
difference in all 
primary outcomes 
evaluated   
1 SAE in 
experiment
al arm  
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[5
5] 
184; 
64  
Knee 
OA 
1:1  SRL® gel; 1g 
of gel three 
times daily; 
4 weeks  
Piroxicam 
gel 
(Feldene®)  
Pain on walking 
in the previous 
24h assessed 
using VAS, pain 
on palpation 
on the affected 
knee using 
single‐joint 
Ritchie index 
 
No significant 
difference between 
treatment groups in 
the single‐joint Ritchie 
index (p=0.78). 
12 AEs in 
SRL 
16 AEs in 
piroxicam  
Electricity  
[5
6] 
46; 
51  
FM 1:1:
1 
Used Alpha-
Stim CES 
device for 
60 
continuous 
minutes 
each day for 
8 weeks 
1. Sham  
2. Usual 
care alone 
Pain ratings 0-
10 NRS, Short-
Form McGill 
Pain 
Questionnaire, 
Lee’s Fatigue 
Inventory, 
General Sleep 
Disturbance 
Scale, Daily 
Stress 
Inventory, FIQ 
and fMRI 
 
Individuals using the 
active device had a 
greater decrease in 
average pain (p =0 
.023) than individuals 
using the sham device 
or receiving usual care 
alone over time. 
Individuals using an 
active CES device had 
a decrease in 
activation in the pain 
processing regions of 
the brain compared to 
those using a sham 
device based on fMRI 
analyses of 6 
participants. 
Not 
reported  
[5
7] 
30; 
51  
RA 1:1  Exposure to 
EF-HVAC for 
20 min/ day; 
2 weeks 
Sham-
apparatus 
DAS-CRP 
 
DAS28 score 
comparison between 
two groups at 12 
weeks after treatment 
was 
not significant.  
 
No AEs 
related to 
treatment  
Nonvitamin, nonmineral, natural products 
[5
9] 
240; 
48  
Sjögr
en's 
synd
rome 
2:1 ShengJinRu
nZaoYangXu
e granules; 
Once daily; 
6 weeks  
Placebo Salivary flow 
rate, Schirmer 
test results and 
sugar test 
result  
 
For Schirmer test, the 
between-group and 
within-group before-
and after paired 
comparison results 
were statistically 
significant (p<0.05).  
.  
4% 
treatment-
related AEs 
in 
experiment
al group vs 
0% in 
control 
group 
[5
8] 
52; 
59  
FM 1:1 DHEA; 50 
mg/day; 1 
month  
Placebo Quality of life 
measured by 
PGWBI 
 
No significant 
difference between 
treatment and 
placebo in any of the 
primary evaluated.   
Androgenic 
side effects 
were more 
common 
with DHEA  
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[6
0] 
176; 
52 
Gout  1:1 Chuanhu 
anti-gout 
Mixture; 
250 ml/day: 
12 weeks  
Colchicine Recurrence 
rate of acute 
gouty arthritis 
Chuanhu anti-gout 
mixture 
was not inferior to 
Colchicine.  
Rates of 
total AEs 
were 
3.27% and 
28.41% in 
CH group 
and Col 
group 
[6
1] 
46; 
36 
SLE 1:1 Convention
al medicines 
and 100% 
TCM 
(LWDHW 
and Dan-Chi 
San) 
Conventio
nal 
medicines 
and 10% 
TCM  
Steroid dosage 
after 6 months 
of combined 
therapy 
Change in steroid dose 
was not statistically 
significant in either 
group.  
No 
difference in 
the 
frequency 
of AEs 
between 
both groups  
[6
2] 
125; 
48 
IBS-C 1:1  Chinese 
Herbal 
Medicine 
capsule; 10/ 
day; 8 
weeks  
Placebo Global 
symptom 
improvement 
 
68% of CHM group 
and 43% of placebo 
group changed from 
no relief to adequate 
relief (p = 0.010). 
6 AEs 
potentially 
associated 
with the 
study drug,  
[8
6] 
150; 
59.3  
RA 1:1:
1 
Non
-
infe
riori
ty 
6 borage 
seed oil 
capsules 
plus 7 
sunflower 
seed oil 
capsules 
daily; 18 
months  
1. Fish oil 
and 
sunflower  
seed oil 
capsules 
2. Borage 
seed oil 
and fish oil 
capsules 
DAS-28 
 
The premise of 
combination of borage 
and fish oils would be 
superior to either oil 
alone is not 
confirmed. 
With fish as 
the 
reference 
group, 
borage IRR = 
1.56 and 
combined 
IRR = 2.61 
[8
7] 
192; 
47  
RA 1:1:
1:1 
Tripterygiu
m wilfordii 
based 
therapy  
1. GTT; 10 
mg  3 times 
a day; 24 
weeks  
2. YSJB pill; 
8g/each 
time and 3 
times a day; 
24 weeks 
3. Placebo 
of MTX and 
SSZ; 24 
weeks 
1. MTX 
2. SSZ3 
Placebo of 
GTT and 
YSJB 
ACR20 at week 
24 
 
RR value is 1.2791 in 
predictor positive 
group based on ACR 
20 response (p = 
0.0492).  
 
AE 
TwHF/P+: 
26.9% 
M&S/P+ : 
35.9% 
TwHF/P−: 
25.2% 
M&S/P−: 
25.5% 
[6
8] 
61; 
41  
RA 1:1 Topical T. 
wilfordii; 6 
weeks 
Placebo Modified ACR-
20 response 
rate  
 
Modified ACR-20 
response rate differed 
significantly between 
topical TW (58%) vs 
placebo (20%) (p= 
0.002). There was an 
Not 
reported 
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CE
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8.1-fold increase in 
the modified ACR20 
response for the TW 
compared to the 
placebo group. 
[7
5] 
69; 
60 
RA 1:1 Ambrotose 
Complex 
containing 
dPP; 
1.3 g/day; 6 
months 
Placebo  Changes in the 
DAS score from 
baseline  to 
end of 
treatment  
 
No significant 
difference in primary 
outcomes between 
the experimental and 
placebo groups  
No AEs 
reported  
[6
3] 
118; 
49  
RA 1:1 TLHS 
capsules; 
4.8, 3.6, or 
2.4 g/day; 8 
weeks  
Placebo  ACR20 
 
After 8 weeks, TLHS 
4.8 g and 3.6 g groups 
had significantly 
higher improvement 
rates in ACR20 than in 
the placebo group (all 
p <0.05).  
 
ADR  
4.8g: 3.4%; 
3.6g: 1.7%; 
2.4g: 3.4%; 
Placebo: 
1.7% 
[7
6] 
65; 
28  
RA 1:1 Ganoderma 
lucidum and 
SMS; 4g and 
2.4g/day 
respectively
; 24 weeks  
Placebo Number of 
patients 
achieving 
ACR20 
response 
 
No significant 
difference in ACR20 
response between 
experimental and 
control groups.  
No reports 
of SAEs 
[8
3] 
183; 
52  
RA 1:1 
Dou
ble 
dum
my. 
Non
- 
infe
riori
ty  
SKI306X; 
200 mg/day; 
6 weeks  
Celecoxib  Change in 
patient 
assessment 
of pain using 
VAS 
 
SKI306X was not 
inferior to celecoxib.  
 
Drug-
related AEs: 
29.7% 
patients in 
the SKI306X 
group VS 
23.9% 
patients in 
the 
celecoxib. 
[7
7] 
58; 
46  
RA 1:1 Andrograph
olides; 
30mg three 
times a day; 
14 weeks 
Placebo  Reduction of 
joints pain, 
stiffness, VAPS, 
EULAR and 
duration of 
morning 
stiffness 
 
No significant 
difference in intensity 
of joint pain between 
the experimental and 
control groups. 
 
9 AEs in 
control 
group 
11 AEs in 
experiment
al group  
[7
8] 
39; 
43  
RA 1:1 Nigella 
sativa oil 
capsules; 
1000mg/da
y;8 weeks  
Placebo  Biochemical 
analysis of 
blood, 
measurements 
of cytokine 
levels, 
antioxidant 
defense and 
oxidative stress 
 
No significant 
difference between 
two groups at the 
baseline or end of the 
study for all other 
measurements (all 
p>0.05).  DAS28 score 
was significantly lower 
in the N. sativa group 
as compared with the 
No SAE 
reported AC
CE
PT
ED
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placebo group at the 
end of the study (p- 
value not reported). 
[6
4] 
89; 
56.6  
RA 1:1 Capsulated 
rose-hip 
powder; 
5g/day; 6 
months 
Placebo  HAQ- DI at 6- 
month 
 
Mean change in HAQ-
DI of patients in the 
treatment group 
improved whereas in 
the placebo group it 
worsened (p=0.014 
and p=0.032).  
14 reports 
on side 
effects in 
experiment
al  group 
and 26 
reports in 
placebo 
[7
9] 
65; 
37 
RA 1:1 ALA; 1200 
mg/day; 8 
weeks  
Placebo  Inflammatory 
biomarkers 
including 
serum hs-CRP, 
TNF-α, IL-6, 
and serum 
MMP-3 as a 
marker of joint 
erosion 
No significant 
difference were 
observed in serum 
levels of hs-CRP, TNF-
a, IL-6, and MMP-3 
within and between 
the ALA and placebo 
groups (p > 0.05). 
No SAEs of 
treatment 
was 
reported  
[6
5] 
42; 
58.4  
Knee 
OA 
1:1 Marhame-
Mafasel 
pomade; 
1.5g; every 8 
hours over 6 
weeks 
Placebo Pain, physical 
function and 
stiffness 
measured by 
WOMAC 
 
Significant difference 
between Marhame-
Mafasel and placebo 
groups for pain, 
physical function, 
stiffness and disease 
severity (p < 0.05). 
Effect size of 0.40 for 
pain reduction, 0.32 
and 0.38 for improving 
physical function and 
stiffness, respectively. 
4.76% 
patients in 
experiment
al group 
experienced 
adverse 
reactions as 
compared 
to 0% in 
placebo 
group. 
[6
6] 
60; 
54 
Knee 
OA 
1:1 Aflapin®; 
100mg/day; 
30 days 
Placebo Functional 
disability  
Significant 
improvements in pain 
and function scores 
were observed in 
treatment group 
supplemented with 
100 mg/day of Aflapin 
when compared to 
either baseline or 
placebo. 
No SAEs 
reported 
[8
0] 
92; 
60  
Knee 
OA 
1:1 HLXL 
capsules; 
4000 
mg/day for 
week 1 and 
2, and 5600 
mg/day for 
week 3 to 8; 
8 weeks 
Placebo  Changes in the 
VAS version of 
WOMAC pain 
and function 
score 
No significant 
between-group 
differences in all 
outcomes evaluated.  
HLXL: 35 AEs 
reported  
Placebo: 29 
AEs 
reported  
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[6
7] 
133; 
65 
Knee 
OA 
1:1 4Jointz 
cream; 3.5 
g/day; 12 
weeks  
Placebo  4Jointzwas 
superior to 
placebo at 
12 weeks for 
change in: 
knee pain using 
the pain 
intensity VAS 
and the pain 
scale from the 
KOOS 
Questionnaire; 
markers of 
inflammation 
(IL-6), and 
cartilage 
breakdown 
(CTX-2). 
Pain scores 
significantly reduced 
in the group who 
received 4Jointz 
compared to the 
group who 
received placebo after 
12 weeks using both 
the VAS (-9.9 mm, 
p=0.034) and the 
KOOS pain scale 
(+5.7, p=0.047). 
Changes in IL-6 and 
CTX-2 were not 
significant (-0.04, 
p=0.5; -0.01, p=0.68). 
Local rash 
that was 
more 
common 
amongst 
participants 
receiving 
4Jointz (21% 
vs 1.6%, IRR 
13.2, p= 
0.013) 
[8
4] 
198; 
62 
Knee 
OA 
1:1 
Dou
bled
um
my. 
Non
- 
infe
riori
ty. 
GCSB-5; 
600mg/day; 
12 weeks  
Celecoxib Change in total 
WOMAC score  
GCSB-5 is comparable 
to Celecoxib in terms 
of the efficacy and 
safety. 
Incidence 
of ADRs 
were 31.3% 
and 21.2% 
in 
experiment
al and 
control 
group 
respectively 
[7
4] 
59; 
63  
Knee 
OA 
1:1 Topical Gln 
and 
chondroitin 
preparation; 
8 weeks 
Placebo Participant 
pain rating 
based on a 100 
mm VAS that 
was assessed in 
the clinic at 0, 
4, and 8 weeks 
 
VAS scores indicated a 
greater mean 
reduction in pain for 
experimental group 
compared to placebo 
after 8 weeks. After 4 
weeks the difference 
between active and 
placebo groups in 
their mean reduction 
from baseline was 1.2 
(p <0.05) and after 8 
weeks was 1.8 (p< 
0.01). 
AEs 
appeared to 
be of a 
minor 
nature and 
were 
equally 
distributed 
between 
the 2 groups 
[8
1] 
158
3; 
59  
Knee 
OA  
1:1:
1:1:
1 
Gln; 500mg/ 
day; 24 
weeks + 
CSPG/ 400 
mg/day; 24 
weeks  
1. Placebo  
2. Gln 
3. CSPG  
4. 
Celecoxib 
20% decrease 
in the summed 
score for 
WOMAC pain 
subscale from 
baseline to 
week 24 
No significant 
difference between 
treatment and 
placebo in reducing 
knee pain by 20%. 
 
AEs were 
mild, 
infrequent, 
and evenly 
distributed 
among the 
groups. 
[8
2] 
95; 
54 
Knee 
OA 
1:1 Reparagen; 
1800mg/da
y; 8 weeks  
 
Gln; 1500 
mg/day; 8 
weeks  
 
Response rate 
based on a 20% 
The response rates 
were substantial for 
both glucosamine and 
reparagen. 
No SAEs 
were 
noted 
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improvement 
in WOMAC 
pain scores 
[7
2] 
50; 
68  
Knee 
OA 
1:1 MSM; 1.125 
grams 3 
times daily; 
12 weeks 
Placebo WOMAC, ALF, 
SF-36, and VAS  
 
Significant difference 
between treatment 
groups over time in 
WOMAC physical 
function (p = 0.04) and 
in WOMAC total score 
(p = 0.03). No 
significant differences 
between groups in 
WOMAC pain (p = 
0.08), WOMAC 
stiffness (p = 0.08), SF-
36 total score (p = 
0.54).  
  
No AEs 
recorded 
[8
5] 
64; 
69  
Knee 
OA 
1:1 
Non
- 
infe
riori
ty. 
Collagen 
MD-Knee; 
two vials for 
a total of 4 
ml via intra-
articular 
injection, 
once a 
week; 5 
weeks 
Intra-
articular 
injection 
of sodium 
hyaluronat
e 
LKI at T0, 3 
month and 6 
month follow-
up 
 
Treatment with MD-
Knee was not inferior 
of the treatment with 
SUPARTZ® (sodium 
hyaluronate). 
1 subject 
discontinue
d for a 
moderate 
post-
injection 
reaction in 
experiment
al group  
[7
3] 
69; 
52 
Knee 
OA 
1:1  L-carnitine 
Tartrate; 
750 mg /day 
divided into 
3 equal 
doses of one 
250-mg 
tablet; 8 
weeks  
Placebo  Pain intensity 
assessed using 
a 0- to 100-mm 
VAS scale and 
PGA of the 
severity of 
knee OA 
Significant difference 
between the 2 groups 
for mean pain 
intensity and PGA of 
the severity of knee 
OA  
(p< 0.05) 
 
No 
participants 
reported 
any AEs 
[6
9] 
215; 
60  
Hand 
OA  
1:1 
 
Oral GCSB-
5; 600 mg/ 
day; 12 
weeks  
Placebo  Change in 
AUSCAN pain 
score at 4 
weeks relative 
to baseline 
 
Improvements in the 
AUSCAN pain score 
were significantly 
greater in the GCSB-5 
group than in the 
placebo group over 
the 16-week study 
period (P = 0.0052).  
.  
AE 
GCSB-5: 
55% 
Placebo: 
45% 
[1
6] 
345; 
62  
Hip 
OA 
1:1 Avocado–
soybean 
unsaponifia
ble—
Expanscienc
e (ASU-E); 
Placebo Mean change 
in JSW on the 
AP target hip 
view at year 3 
 
No statistically 
difference in adjusted 
mean JSN at year 3 
(p=0.72). 
 
10.1% 
patients in 
experiment
al group has 
≥1 
treatment 
related AEs 
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300mg/day; 
3 years 
compared 
to 6.2% in 
control  
[7
0] 
94; 
age 
not 
rep
orte
d 
Knee 
and 
hip 
OA 
1:1 Rose‐hip; 
5g/day; 3 
months  
Placebo Pain, stiffness, 
disability, and 
global severity 
of  
disease 
assessed using 
WOMAC  
WOMAC pain, 
disability, stiffness, 
and global severity of 
the disease decreased 
significantly (p< 
0.014, p<0.018, 
p<0.038, and p<0.035, 
respectively) after 3 
months. 
No SAEs in 
experiment
al group  
[7
1] 
78; 
53 
Knee 
and 
hip 
OA 
1:1 Willow bark 
extract; 240 
mg 
salicin/day; 
2 weeks 
Placebo Pain dimension 
of the WOMAC 
OA Index 
Significant difference 
between the active 
treatment and the 
placebo group was 
observed in the 
WOMAC pain 
dimension (d =6.5 
mm, 95% CI= 0.2–12.7 
mm, p = 0.047) 
Skin 
rash starting 
in a patient 
in 
experiment
al group  
Megavitamin therapy  
[9
4] 
34; 
51.7  
FM 1:1 IV Myers' 
cocktail; 
Once 
weekly; 8 
weeks  
 
Placebo  TPI 
 
Between-group 
comparisons of all 
primary outcomes did 
not reach statistical 
significance (all p 
> 0.05). 
1 AE in 
experiment
al group 
[9
2] 
40; 
19 
Juve
nile 
SLE 
1:1 Oral 
cholecalcife
rol; 50,000 
IU/week; 24 
weeks  
Placebo  SLEDAI and 
ECLAM 
At the end of the 
intervention, a 
significant 
improvement in 
SLEDAI (p=0.010) and 
in ECLAM (p=0.006) 
was observed in the 
experimental group 
compared to the 
placebo group. 
No SAEs 
reported 
[9
5] 
167; 
12 
Juve
nile 
RA 
1:1 Ca; 1,000 
mg/day and  
vitamin D; 
400 IU/day; 
24 months  
Placebo Total body 
BMD 
Significantly higher 
total body BMD 
among patients who 
received Ca compared 
with patients who 
received 
placebo during the 
study period (p= 0.03) 
No SAEs 
reported 
[9
3] 
58; 
39 
RA 1:1 Vitamin K1; 
10mg/day; 8 
weeks  
Placebo  Serum levels of 
MMP-3, and RF 
No significant 
differences in serum 
MMP-2 and RF 
between groups  
1 
participant 
in 
experiment
al group 
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experienced 
heartburn  
[8
8] 
599; 
63  
Knee 
OA  
1:1  Vitamin D3; 
50,000 IU/ 
month; 24 
months  
Placebo  WOMAC knee 
pain score and 
change in tibial 
cartilage 
volume on MRI  
No significant 
difference in change in 
MRI-measured tibial 
cartilage volume or 
WOMAC knee pain 
score over 2 years 
4 
participants 
developed 
hypercalce
mia in the 
vitamin D 
group vs 2 in 
the placebo 
group 
[8
9] 
103; 
53 
Knee 
OA  
1:1 Oral 
cholecalcife
rol; 60,000 
IU/day for 
10 days 
followed by 
60,000 IU 
once a 
month for 
12 months 
Placebo Knee pain and 
function 
At 12 months, knee 
pain had decreased in 
the vitamin D group by 
mean -0.26 on VAS 
and -0.55on the 
WOMAC, whereas in 
the placebo group, it 
increased by mean 
0.13 on the VAS and 
1.16 on the WOMAC 
(effect size = 0.37 and 
0.78). Knee function 
improved in the 
vitamin D group by 
mean -1.36 over the 
placebo group which 
had a mean 0.69 
(effect size = 0.06). 
Not 
reported  
[9
0] 
136;
64 
Knee 
OA 
1:1 Vitamin E; 
500 IU/day; 
24 months  
Placebo Change in knee 
cartilage 
volume 
No significant 
difference was found 
between the two 
groups for change in 
knee cartilage volume.  
AEs not 
reported  
[9
1] 
22; 
63 
Knee 
OA 
1:1 Aquamin; 
2400 mg/d; 
12 weeks  
Placebo WOMAC No significant 
difference was found 
between the two 
groups for WOMAC 
pain, stiffness, activity 
or composite 
scores. 
AEs profiles 
were not 
significantly 
different 
between 
the groups 
Chiropractic or osteopathic manipulation  
43
; 
45 
Kne
e 
OA 
1:1 
 
Kine
sio 
tapi
ng 
usin
g “Y- 
strip
”; 
ever
y 
Sham taping 
using 
flexible tape 
Pain 
intensity 
with 
activity 
and at 
night using 
VAS  
No significant 
difference 
between the 
groups VAS for 
activity pain, 
VAS for 
nocturnal pain. 
Not reported   
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four 
days
, 
thre
e 
tim
e 
60
; 
82 
CM
C 
join
t OA 
1:1  Mul
tim
odal 
man
ual 
trea
tme
nt; 
12 
sess
ions
;  4 
wee
ks 
Sham 
treatment 
with 
ultrasound 
at 0 
watts/cm2 
Pain 
intensity 
of the first 
CMC joint 
assessed 
using VAS 
Patients in the 
experimental 
group 
experienced a 
significantly 
greater 
reduction in 
pain compared 
to the placebo 
group 
(p<0.001). 
No AEs detected   
28
;8
2 
TCO
A 
1:1  Mai
tlan
d's 
pass
ive 
acce
ssor
y 
mob
iliza
tion
; 4 
sess
ions
; 2 
wee
ks 
Sham 
treatment 
with 
ultrasound 
at 0 
watts/cm2 
Pain 
threshold 
measurem
ent  
In the treated 
group, pain 
threshold in 
the TMJ 
increased after 
treatment and 
was 
maintained at 
the same level 
during the first 
FU and second 
FU. All values in 
sham group 
remained 
unchanged. 
No AEs detected  
Energy healing therapy  
[9
9] 
45; 
68 
OA  1:1 
Cros
sov
er 
Magnetic 
wrist strap; 
minimum of 
8 hours/ 
day; 4 
weeks  
Weak 
magnetic 
wrist strap 
WOMAC OA 
Index, McGill 
Pain 
Questionnaire
— 
PRI, a pain VAS, 
and 
medication use 
No significant 
difference was 
observed between 
devices in terms of 
their effects on pain as 
measured by the 
primary outcome 
measure (WOMAC A), 
the PRI and the VAS as 
well as stiffness, 
physical function, and 
medication use.  
No AEs 
reported 
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Abbreviations 
ACPA: Anti-citrullinated protein antibodies; ACR20: American College of Rheumatology 20% improvement criteria; 
ADR: Adverse drug reaction; AE: Adverse event; AIMS2: Arthritis Impact Measurement Scale; ALA: Alpha-lipoic acid; 
ALF: Aggregated Locomotor Function; AP: Anteroposterior; AUSCAN: Australian Canadian Osteoarthritis Hand Index; 
BDI: Back Depression Inventory; BMD: Bone mineral density; BPI: Brief Pain Inventory; Ca: Calcium; CES: Cranial 
electrical stimulation; CD: Cluster of differentiation; CDAI: Clinical Disease Activity Index; CI: Confidence interval; 
CMC: Carpometacarpal; CPAQ: Chronic Pain Acceptance Questionnaire; CRP: C- reactive protein; CSPG: Chondroitin 
sulfate; DAS: Disease activity score; DER: Drug-to-extract ratio; DHA: Docosahexaenoic acid; DHEA: 
Dehydroepiandrosterone; DI: Disability index; dPP: Dietary plant- derived polysaccharides; EA: Electroacupuncture;  
ECLAM: European Consensus Lupus Activity Measurement; EF-HVAC: Electric field by high voltage alternating 
current; EPA: Eicosapentaenoic acid; ESR: Erythrocyte sedimentation rate; EULAR: European League Against 
Rheumatism response criteria; FAS: Full analysis set; FIQ: Fibromyalgia Impact Questionnaire; FM: Fibromyalgia; 
fMRI: functional magnetic resonance imaging; FRAP: Ferric-reducing/antioxidant power; FU: Follow-up; GA: Global 
assessment; GHQ: General Health Questionnaire; GLA: Gamma-linolenic acid; Gln: Glucosamine; GTT: Glucosidorum 
Tripterygll Totorum; HAI: Hand algofunctional index; HAQ: Health assessment questionnaire; Hb: Hemoglobin; hs-
CRP: high-sensitivity C-reactive protein; HSQ: Health status questionnaire; HLXL: Huo-Luo-Xiao-Ling; IBS-C: 
constipation-predominant Irritable bowel syndrome; IL: Interleukin; IRR: Incident rate ratio; ITT: Intention-to-treat; 
IU: International unit; IV: Intravenous; JSN: Joint space narrowing; KOOS: Knee Injury and Osteoarthritis Outcome 
Score; LFI: Lequesne's Algofunctional Index; LKI: Lequesne Knee Index; LWDHW: Liu-Wei-Di-Huang Wan; MMP-3: 
Matrix metalloproteinase-3; MPQ: McGill Pain Questionnaire; MPS: Myofascial pain syndrome; MSM: 
Methylsulfonylmethane; MTS: Medial tenderness score; MTX: Methotrexate; NHP: Nottingham Health Profile; NK: 
Natural killer; NRS: Numeric Rating Scale; NSAID: Non-steroidal anti-inflammatory drug; NO: Nitric oxide; OA: 
Osteoarthritis; OMERACT-OARSI: Outcome Measures in Rheumatology–OA Research Society International; PANAS: 
Positive and Negative Affect Scales; PCS: Pain Catastrophizing Scale; PGA: Patient global assessment; PGWBI: 
Psychological General Well Being Index; POMS: Profile of Mood States; PPS: Per-protocol set; PRI: Pain Rating Index; 
pVAS: Pain on movement; QoL: Quality of Life; RA: Rheumatoid arthritis; RF: Rheumatoid factor; RR: Risk ratio; SAE: 
Serious adverse event; SF36: Short form health survey; SGPT: Serum glutamic pyruvic transaminase; SLE: Systemic 
Lupus Erythematosus; SLEDAI: Systemic Lupus Erythematosus Disease Activity Index; SMS: San Miao San; SPPB: Short 
Physical Performance Battery; SRL: Spiroflor; SSZ: Sulfasalazine; SOD: Superoxide dismutase; TAC: Total antioxidant 
capacity; TCA: Traditional acupuncture; TCOA: Thumb carpometacarpal osteoarthritis; TLHS: Tong Luo Hua Shi; TMJ: 
Trapeziometacarpal joint; TNF: Tumour necrosis factor; TPI: Tender point index; VAPS: Visual analog pain scale; VAS: 
Visual analog scale; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index; YSJB: Yi Shen Juan 
Bi 
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